# CAR-T Cells in the Treatment of Malignant Hematological Tumors

> **NCT05619861** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma, B-Cell
- Leukemia, B-cell
- Leukemia, T-Cell
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CAR-T

## Key facts

- **NCT ID:** NCT05619861
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-27
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-12-26
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05619861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05619861, "CAR-T Cells in the Treatment of Malignant Hematological Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05619861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*